» Articles » PMID: 17397912

Demographic and Clinical Characteristics of Children and Adolescents with Severe or Difficult-to-treat Asthma

Overview
Date 2007 Apr 3
PMID 17397912
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Young patients with severe or difficult-to-treat asthma are an understudied population.

Objective: To assess age-associated and gender-associated differences in children and adolescents in the observational study, The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens.

Methods: Cross-sectional baseline data for patients greater than or equal to 6 years and less than or equal to 17 years (n = 1261) were stratified by age group (6-8, 9-11, 12-14, and 15-17 years). The chi(2) test for categorical variables and analysis of variance for continuous variables were used to identify differences among age groups, stratified by gender.

Results: Most patients had moderate (55%) or severe (41%) asthma by physician assessment. Of those using greater than or equal to 3 long-term controllers (62%), 53% of children (6-11 years) and 44% of adolescents (12-17 years) reported an oral corticosteroid burst and 25% and 19%, respectively, had an emergency department visit in the previous 3 months; 10% and 15%, respectively, reported past intubation. In females, weight for age ranged between the 67th and 70th percentiles; height for age was between the 42nd and 54th percentiles (P < .01 among age groups). Lung function was lower in adolescents than children: prebronchodilator percent predicted forced expiratory volume in 1 second (FEV(1))/forced vital capacity was 0.92 (6-8 years) and 0.83 (15-17 years), P less than .05, in males; and 0.94 (6-8 years) and 0.87 (15-17 years), P less than .05, in females.

Conclusions: Children and adolescents demonstrated high rates of health care use and loss of lung function, despite using multiple long-term controllers.

Clinical Implications: Asthma treatments that prevent loss of lung function and reduce health care resource use are needed in young patients with severe or difficult-to-treat asthma.

Citing Articles

Epidemiology of severe asthma in children: a systematic review and meta-analysis.

Manti S, Magri P, De Silvestri A, De Filippo M, Votto M, Marseglia G Eur Respir Rev. 2024; 33(174).

PMID: 39384302 PMC: 11462310. DOI: 10.1183/16000617.0095-2024.


Prediction of Asthma Exacerbations in Children.

Sarikloglou E, Fouzas S, Paraskakis E J Pers Med. 2024; 14(1).

PMID: 38248721 PMC: 10820562. DOI: 10.3390/jpm14010020.


Pyrroloquinoline Quinone Administration Alleviates Allergic Airway Inflammation in Mice by Regulating the JAK-STAT Signaling Pathway.

Min Z, Zhou J, Mao R, Cui B, Cheng Y, Chen Z Mediators Inflamm. 2022; 2022:1267841.

PMID: 36345503 PMC: 9637035. DOI: 10.1155/2022/1267841.


Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS).

Szefler S, Roberts G, Rubin A, Zielen S, Kuna P, Alpan O Clin Transl Allergy. 2022; 12(7):e12176.

PMID: 35846226 PMC: 9281483. DOI: 10.1002/clt2.12176.


Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma-A Romanian Perspective.

Berghea E, Balgradean M, Pavelescu C, Cirstoveanu C, Toma C, Ionescu M Children (Basel). 2021; 8(12).

PMID: 34943337 PMC: 8700741. DOI: 10.3390/children8121141.